Hepion Pharmaceuticals Granted Orphan Drug Designation For Treatment Of Hepatocellular Carcinoma
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=885822
12 Health Care Stocks Moving In Thursday’s After-Market Session
Gainers
Radius Health (NASDAQ:RDUS) stock moved upwards by 18.8% to $6.94 during Thursday's after-market session. The company's market cap stands at $330.1 million.
Hepion Pharma Reports Clinical Collab With HepQuant In Phase 2b NASH Trial
- HepQuant Evaluation Offers Sensitive Measurement of Hepatic Function and Correlation with Clinical Outcomes -
- Dedicated Phase 2b Trial Supports Overarching NASH Program for Rencofilstat -
- Four-Month, Three Arm
12 Health Care Stocks Moving In Wednesday’s After-Market Session
Gainers
Reneo Pharmaceuticals (NASDAQ:RPHM) shares increased by 6.4% to $6.82 during Wednesday's after-market session. The company's market cap stands at $166.5 million.
Hepion’s Rencofilstat Combo Shows Anti-Tumor Activity In Nonclinical Liver Cancer Study
Hepion Pharmaceuticals Inc (NASDAQ: HEPA) has announced the results of a nonclinical research study showing rencofilstat (CRV431)
The Daily Biotech Pulse: Glaukos Gets FDA Nod, Neurocrine Preannounces Soft Ingrezza Sales, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Hepion Pharmaceuticals Announces FDA Clearance Of IND Application For CRV431 In Treatment Of Liver Cancer
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic
Hepion Pharmaceuticals Announces FDA Clearance Of IND Application For CRV431 In The Treatment Of Liver Cancer
- New IND Expands Liver Disease Pipeline for CRV431 -
- IND Clearance Allows CRV431 to Move Directly into Phase 2 for Hepatocellular Carcinoma Treatment -
- New IND Provides for Complementary Therapeutic Approach of
Hepion Pharmaceuticals Says Co’s Anti-Cancer Mechanism CRV431 Highlighted In Scripps Research Institute Poster At AASLD, The Liver Meeting 2021
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic
Hepion’s CRV431 Shows Encouraging Safety Profile In Drug-Drug Interaction Study
Hepion Pharmaceuticals Inc (NASDAQ:HEPA) has announced results from a Drug-Drug Interaction (DDI) study with its lead drug candidate, CRV431. CRV431 targets…